SCHEMBL21495029

SCHEMBL21495029

N#CCC(=O)Nc1nc(-c2ccc(N3CCOCC3)nc2)cs1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.59
SMN1; SMN2 Q16637 4/20 0.59
KMT2A Q03164 3/20 0.59
RAB9A P51151 3/20 0.59
KDM4E B2RXH2 2/20 0.59
ALDH1A1 P00352 2/20 0.59
MEN1 O00255 2/20 0.59
NPC1 O15118 2/20 0.59
ABL1 P00519 1/20 0.55
POLB P06746 2/20 0.50
JAK1 P23458 3/20 0.49
JAK3 P52333 3/20 0.49
JAK2 O60674 2/20 0.49
LMNA P02545 6/20 0.48
HTT P42858 4/20 0.47
USP2 O75604 2/20 0.47
MAPK1 P28482 1/20 0.47
HSD17B10 Q99714 1/20 0.47
NOD2 Q9HC29 1/20 0.45
ATR Q13535 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21484812 0.88 KMT2A (0.63) MAPTSMN1; SMN2KMT2ARAB9AKDM4E
SCHEMBL21495084 0.86 MAPT (0.53) MAPTSMN1; SMN2KMT2ARAB9AKDM4E
SCHEMBL28518770 0.78 LMNA (0.50) MAPTSMN1; SMN2KMT2ARAB9AKDM4E
SCHEMBL21484880 0.78 ABL1 (0.65) MAPTSMN1; SMN2KMT2ARAB9AKDM4E
SCHEMBL3311430 0.76 LMNA (0.60) MAPTSMN1; SMN2KMT2ARAB9AKDM4E
SCHEMBL21484886 0.75 ABL1 (0.61) MAPTSMN1; SMN2KMT2ARAB9AKDM4E
SCHEMBL30186374 0.74 RRM1 (0.49) MAPTSMN1; SMN2KMT2AKDM4EALDH1A1
SCHEMBL21484800 0.74 KMT2A (0.69) MAPTSMN1; SMN2KMT2ARAB9AKDM4E
SCHEMBL21484734 0.74 ABL1 (0.69) MAPTSMN1; SMN2KMT2ARAB9AKDM4E
SCHEMBL21484695 0.74 ABL1 (0.69) MAPTSMN1; SMN2KMT2ARAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 US disclosed
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-01-06 US disclosed
CN-112313229-A Substituted aminothiazoles as inhibitors of nucleases 马萨里克大学 2021-02-02 CN disclosed
WO-2019201865-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 WO disclosed
WO-2019201865-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases RNASEH1, DNASE1, FEN1 MAPT 706/4885SMN1; SMN2 104/4885KMT2A 805/4885
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES RNASEH1, DNASE1, FEN1 MAPT 706/4885SMN1; SMN2 104/4885KMT2A 805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.